Introduction ALK gene rearrangement in NSCLC results from fusion with another partner gene, mainly EML4 gene, and is observed in less than 5% of adenocarcinoma tumors. Patients usually manifest a response to ALK tyrosine kinase inhibitors. Unfortunately, acquired resistance ineluctably occurs and has been associated with the emergence of secondary mutations.1 Here, we report the identification of an ALK resistance mutation in a patient with ALK tyrosine kinase inhibitor–naive multimetastatic NSCLC. Conclusions ALK secondary resistance mutations can be present in naive tumors and may be associated with aggressive presentation. Baseline NGS screening is very important to identify uncommon mutations and improve first-line targeted therapeutic strategies. READ ARTICLE
JTO Clinical and Research Reports DOI:10.1016/j.jtocrr.2020.100047
Authors: Olfa Trabelsi-Grati, Elsy El-Alam, Samia Melaabi, Yves Allory, Ivan Bièche, Nicolas Girard, Céline Callens,